Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 17, keine Gesamtzahl für „Table“
Suchtreffer
Begriffe & Kennungen
CellCept · 4.3 · 25 • Treatment should not be used in pregnancy unless there is no suitable alternative treatment to prevent tr
Eintrag öffnenCellCept · 4.3 · • Treatment should not be used during pregnancy unless there is no suitable alternative treatment to prevent t
Eintrag öffnenCellCept · 4.3 · • Treatment should not be used in pregnancy unless there is no suitable alternative treatment to prevent trans
Eintrag öffnenCellCept · 4.3 · • Treatment should not be used in pregnancy unless there is no suitable alternative treatment to prevent trans
Eintrag öffnenCellCept · 4.8 · 53 Table 2 Adverse reactions in studies investigating mycophenolate mofetil treatment in adults and adolescent
Eintrag öffnenCellCept · 4.8 · Table 1 Adverse reactions in studies investigating mycophenolate mofetil treatment in adults and adolescents,
Eintrag öffnenCellCept · 4.8 · Table 1 Adverse reactions in studies investigating mycophenolate mofetil treatment in adults and adolescents,
Eintrag öffnenCellCept · 4.8 · Table 1 Adverse reactions in studies investigating mycophenolate mofetil treatment in adults and adolescents,
Eintrag öffnenCellCept · 4.8 · Table 2 Summary of adverse reactions observed more frequently in a trial investigating mycophenolate mofetil i
Eintrag öffnenCellCept · 4.8 · Table 2 Summary of adverse reactions observed more frequently in a trial investigating mycophenolate mofetil i
Eintrag öffnenCellCept · 4.8 · Table 3 Summary of adverse reactions observed more frequently in a trialinvestigating mycophenolate mofetil in
Eintrag öffnenCellCept · 4.8 · The adverse reactions from clinical trials and post-marketing experience are listed in Table 1, by MedDRA syst
Eintrag öffnenCellCept · 4.8 · The adverse reactions from clinical trials and post-marketing experience are listed in Table 1, by MedDRA syst
Eintrag öffnenCellCept · 4.8 · The adverse reactions from clinical trials and post-marketing experience are listed in Table 1, by MedDRA syst
Eintrag öffnenCellCept · 4.8 · The adverse reactions from clinical trials and post-marketing experience are listed in Table 2, by MedDRA syst
Eintrag öffnenCelsentri · 4.5 · 34 Table 2: Interactions and adulta dose recommendations with other medicinal products
Eintrag öffnenCelsentri · 4.5 · 7 Table 2: Interactions and adulta dose recommendations with other medicinal products
Eintrag öffnenCelsentri · 4.8 · Table 3: Adverse reactions observed in clinical trials or post-marketing
Eintrag öffnenCelsentri · 4.8 · Table 3: Adverse reactions observed in clinical trials or post-marketing
Eintrag öffnenCelsentri · 4.8 · Table 4 shows the incidence ≥1% of Grade 3-4 Abnormalities (ACTG Criteria) based on the maximum shift in labor
Eintrag öffnen